Clinical Challenges of the COVID-19 Vaccines: Frequency of Serious Adverse Events After Immunization in Hospitalized Patients

Article Type:
Research/Original Article (دارای رتبه معتبر)
Background and aims

 Today, the role of coronavirus disease 19 (COVID-19) vaccines in preventing the disease and reducing the severity of the disease is undeniable; however, there is a possibility of serious adverse events following immunization (sAEFI) that might be life-threatening. The present study was designed to identify the frequency of the most common sAEFI in hospitalized people after receiving the COVID-19 vaccine in the south of Iran.


 This cross-sectional study was conducted in 2022. In total, since the start of the COVID-19 vaccination program in the city of Larestan, in the south of Iran, a total of 68 sick people have been hospitalized due to complications caused by the vaccine. The research tool of the present study was a standard checklist called the sAEFI of the COVID-19 vaccine.


 A total of 68 hospital cases were reviewed. The mean age of the individuals with sAEFI was 59.78±12.70 years, and 21 (56.8%) of them were females. Acute respiratory distress syndrome (ARDS) was the most common 24 (64.9%) sAEFI. Based on the results, 2 (5.4%) had acute coronary syndrome (ACS), 2 (5.4%) had Guillain-Barré syndrome, and 2 (5.4%) had a stroke.


 It can be mentioned that there is always a possibility of sAEFI, but its frequency in the general population is extremely rare. However, the most common sAEFIs included adverse drug reactions, stroke, and Guillain-Barré syndrome. The readiness of health care staff for early detection of possible sAEFI can be effective in reducing the severity of the sAEFI.

Epidemiology and Health System Journal, Volume:10 Issue: 4, Autumn 2023
175 to 179  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!